4-氨基-3,5-双(三氟甲基)联苯 | 444143-45-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-3,5-双(三氟甲基)联苯
• 中文别名: 4-氨基-3',5'-双(三氟甲基)联苯；3',5'-双(三氟甲基)[1,1'-联苯]-4-胺
• 英文名称: 3',5'-bis(trifluoromethyl)-[1,1'-biphenyl]-4-amine
• 英文别名: 4-amino-3',5'-bis(trifluoromethyl)biphenyl；4-[3,5-bis(trifluoromethyl)phenyl]aniline
• CAS: 444143-45-7
• 化学式: C₁₄H₉F₆N
• mdl: MFCD05154989
• 分子量: 305.223
• InChiKey: MGGUROGTKGUOGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2921499090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 3',5'-BIS(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-4-
YLAMINE
CAS-No. : 444143-45-7
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 2)
Serious eye damage (Category 1)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Toxic if swallowed. Risk of serious damage to eyes.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
H300 Fatal if swallowed.
H318 Causes serious eye damage.
Precautionary statement(s)
P264 Wash hands thoroughly after handling.
P280 Wear protective gloves/ eye protection/ face protection.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R25 Toxic if swallowed.
R41 Risk of serious damage to eyes.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S39 Wear eye/face protection.
S45 In case of accident or if you feel unwell, seek medical advice immediately
(show the label where possible).
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C14 H9 F6 N
Molecular Weight : 305,23 g/mol
Component Concentration
3',5'-BIS(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-4-YLAMINE
CAS-No. 444143-45-7 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate
ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point not applicable
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be fatal if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes Causes eye burns.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (3',5'-BIS(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-4-
YLAMINE)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (3',5'-BIS(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-4-
YLAMINE)
IATA: Toxic solid, organic, n.o.s. (3',5'-BIS(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-4-YLAMINE)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  4-氨基-3,5-双(三氟甲基)联苯 在 N-溴代丁二酰亚胺(NBS) 、 硫酸 、 sodium nitrite 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 3,5-dibromo-3',5'-bis(trifluoromethyl)-1,1'-biphenyl
  参考文献：
  名称：

  一种含间三联苯结构二胺化合物及其合成方 法和应用

  摘要：

  本发明公开的是一种含间三联苯结构二胺化合物及其合成方法和应用。本发明利用卤代芳烃经Suzuki反应引入一个氨基后，通过溴代、重氮化、Suzuki偶联、还原得到含间三联苯结构的功能二胺化合物。该二胺化合物合成方法工艺简单，产率较高，所合成的化合物具有一定的荧光特性。本发明的二胺化合物可用于合成如聚酰胺、聚酰亚胺、聚酰胺酰亚胺和聚酯酰亚胺等高性能、功能化聚合物，特别适合于制备可溶性、无色透明并具有一定荧光特性的高性能功能聚酰亚胺材料。

  公开号：

  CN104016870B
• 作为产物：
  描述：

  3,5-双三氟甲基溴苯 在 正丁基锂 、 tin(ll) chloride 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 乙酸乙酯 为溶剂， 反应 22.0h， 生成 4-氨基-3,5-双(三氟甲基)联苯
  参考文献：
  名称：

  通过烷基取代基将诱变的芳香胺转化为非诱变物种。第二部分：远离氨基官能团的烷基化。

  摘要：

  合成了4-氨基联苯（1）（4ABP）和2-氨基芴（7）（2AF）的烷基和三氟甲基衍生物，并使用鼠伤寒沙门氏菌测试仪菌株TA98和TA100在添加和不添加S9混合物的情况下进行了诱变分析。1的修饰是通过在4'-位置，3'-位置（烷基）上连接烷基（甲基，乙基，异丙基，正丁基，叔丁基）和三氟甲基（CF（3））来实现的Me，CF（3））和3'-，5'-位置（DiMe，DiCF（3））。通过在7位引入烷基（甲基，叔丁基，金刚烷基）和三氟甲基（CF（3））对化合物7进行修饰。1和7的导数表明，对于空间需求增长的组，诱变活性降低。最大的组（CF（3），叔丁基和金刚烷基）诱变上最强的影响。通过引入这样的取代基甚至可以消除1和7的诱变性。在工作的最后一部分，我们将实验诱变性与从QSAR相关性得出的计算值进行了比较。我们的发现表明，对于具有大取代基的芳族胺的预测通常过高。在CF（3）-，叔丁基-和金刚烷基中观

  DOI：

  10.1016/s1383-5718(01)00345-x

文献信息

• ω-Phthalimidoalkyl Aryl Ureas as Potent and Selective Inhibitors of Cholesterol Esterase
  作者：Florian M. Dato、Miriam Sheikh、Rocky Z. Uhl、Alexandra W. Schüller、Michaela Steinkrüger、Peter Koch、Jörg-Martin Neudörfl、Michael Gütschow、Bernd Goldfuss、Markus Pietsch

  DOI：10.1002/cmdc.201800388

  日期：2018.9.6

  with an attached 3,5‐bis(trifluoromethyl)phenyl group and the aromatic character of the ω‐phthalimide residue were most important for inhibitory activity. In addition, an alkyl chain composed of three or four methylene groups, connecting the urea and phthalimide moieties, was found to be an optimal spacer for inhibitors. The so‐optimized compounds 2 [1‐(3,5‐bis(trifluoromethyl)phenyl)‐3‐(3‐(1,3‐di

  胆固醇酯酶（CEase）是一种丝氨酸水解酶，被认为与动脉粥样硬化有关，因此与冠心病有关，被认为是抑制剂发展的目标。在一个小的ω-邻苯二甲酰亚胺基烷基芳基尿素文库的结构-活性关系研究中，我们用新的荧光测定法研究了重组人和鼠类CEase。带有3,5-双（三氟甲基）苯基的尿素基序和ω-邻苯二甲酰亚胺残基的芳香特性对于抑制活性最重要。另外，发现由三个或四个连接尿素和邻苯二甲酰亚胺部分的亚甲基组成的烷基链是抑制剂的最佳间隔基。如此优化的化合物2 [1-（3,5-双（三氟甲基）苯基）-3-（3-（1,3-二氧代异吲哚啉-2-基）丙基）脲]和21[1-（3,5-双（三氟甲基）苯基）-3-（4-（1,3- dioxoisoindolin -2-基）丁基）脲]显示解离常数（ķ我的1-19μ）米上的两种CEase并显示出竞争性抑制作用（对人类酶而言为2种，对鼠类酶而言为21种）或非竞争性抑制方式。ω-邻苯二甲
• 三唑萘醌联芳环衍生物或三唑萘醌联芳杂环 衍生物及其制备方法和用途
  申请人：四川大学

  公开号：CN108467370B

  公开（公告）日：2021-11-23

  本发明属于化学医药领域，具体涉及抗恶性肿瘤、抗急性白血病和关节炎、多发性硬化症和免疫排斥反应小分子及其制备方法和用途。本发明要解决的技术问题是目前临床上二氢乳酸脱氢酶抑制剂小分子上市药物和及其现有其他药理模型的化合物毒副作用大的缺点。本发明解决上述技术问题的方案是提供了一种三唑萘醌联芳环衍生物或三唑萘醌联芳杂环衍生物，该衍生物主要是与三唑连接不同联芳环或联芳杂环，发明提供的化合物具有抗恶性肿瘤活性高且毒副作用低，并能克服临床耐药的优点，在针对治疗恶性肿瘤药物开发上具有很大的价值。
• Bifunctional Naphtho[2,3-<i>d</i>][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects In Vitro and In Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production
  作者：Zeping Zuo、Xiaocong Liu、Xinying Qian、Ting Zeng、Na Sang、Huan Liu、Yue Zhou、Lei Tao、Xia Zhou、Na Su、Yamei Yu、Qiang Chen、Youfu Luo、Yinglan Zhao

  DOI：10.1021/acs.jmedchem.0c00512

  日期：2020.7.23

  Human dihydroorotate dehydrogenase (hDHODH) is an attractive target for cancer therapy. Based on its crystal structure, we designed and synthesized a focused compound library containing the structural moiety of 1,4-benzoquinone, which possesses reactive oxygen species (ROS) induction capacity. Compound 3s with a naphtho[2,3-d][1,2,3]triazole-4,9-dione scaffold exhibited inhibitory activity against

  人二氢乳清酸酯脱氢酶（h DHODH）是癌症治疗的诱人靶标。基于其晶体结构，我们设计并合成了包含1，4-苯醌结构部分的聚焦化合物文库，该化合物具有活性氧（ROS）诱导能力。具有萘[2,3- d ] [1,2,3]三唑-4,9-二酮骨架的化合物3s表现出对h DHODH的抑制活性。进一步优化导致化合物11k和11l抑制h DHODH活性，IC 50值分别为9和4.5 nM。蛋白质-配体共晶体结构清楚地描述了氢键和疏水相互作用11K和11升与ħ DHODH。化合物11k和11l显着抑制白血病细胞和实体瘤细胞增殖并诱导ROS产生，线粒体功能障碍，细胞凋亡和细胞周期停滞。化合物11l的纳米结晶在Raji异种移植模型中显示出显着的体内抗肿瘤作用。总的来说，该研究提供了具有h DHODH抑制和ROS诱导功效的新型双功能化合物11l，其代表了有希望的抗癌药物，值得进一步探索。
• ω-Quinazolinonylalkyl aryl ureas as reversible inhibitors of monoacylglycerol lipase
  作者：Florian M. Dato、Jörg-Martin Neudörfl、Michael Gütschow、Bernd Goldfuss、Markus Pietsch

  DOI：10.1016/j.bioorg.2019.103352

  日期：2020.1

  The serine hydrolase monoacylglycerol lipase (MAGL) is involved in a plethora of pathological conditions, in particular pain and inflammation, various types of cancer, metabolic, neurological and cardiovascular disorders, and is therefore a promising target for drug development. Although a large number of irreversible-acting MAGL inhibitors have been discovered over the past years, there are only few

  丝氨酸水解酶单酰基甘油脂肪酶（MAGL）涉及多种病理状况，特别是疼痛和炎症，各种类型的癌症，代谢，神经和心血管疾病，因此是药物开发的有希望的靶标。尽管在过去几年中发现了许多不可逆作用的MAGL抑制剂，但到目前为止，只有很少的已知化合物可逆地抑制酶。因此，在显示出可逆的抑制行为的新型化学实体上投入了大量的精力，认为这种化学实体引起较少的不良副作用。为了探索各种化学结构作为MAGL粘合剂，我们已经应用了一种虚拟筛选方法，即将小分子停靠在人类MAGL（hMAGL）的晶体结构中，并设想了45种选定化合物的库，然后将其合成。生化研究包括确定对hMAGL和两种相关水解酶的抑制能力，即人脂肪酸酰胺水解酶（hFAAH）和鼠类胆固醇酯酶（mCEase）。这些分析中最有希望的候选物，即三个带有3至5个亚甲基的烷基间隔基的ω-喹唑啉酮烷基烷基芳基脲，IC50值为20-41 µM，对hMAGL具有可逆的去污剂不敏
• 3차 아민 유도체 및 이를 포함한 유기 전계 발광 소자
  申请人：주식회사 랩토

  公开号：KR20220030351A

  公开（公告）日：2022-03-11

  UV영역의 고에너지 외부광원을 효과적으로 흡수하여 유기 전계 발광 소자 내부의 유기물들의 손상을 최소화함으로써 유기 전계 발광 소자의 실질적인 수명 향상에 기여하는 3차 아민 유도체를 제공한다. 본 발명에 따른 유기 전계 발광 소자는, 제1 전극; 제2 전극; 상기 제1 전극과 제2 전극 사이에 배치된 1층 이상의 유기물층; 및 캡핑층을 포함하고, 상기 캡핑층은 하기 화학식 1로 표시되는 3차 아민 유도체를 포함한다. [화학식 1] (상기 화학식 1에서 각 치환기들은 발명의 상세한 설명에서 정의한 바와 같다.)

  这段文字是关于一种提供第三类胺衍生物，通过有效吸收UV区域的高能量外部光源，最小化有机发光器件内部有机物的损伤，从而提高有机发光器件的实际寿命的技术。根据本发明，有机发光器件包括第一电极；第二电极；在所述第一电极和第二电极之间设置的1层以上的有机物层；以及封装层，所述封装层包括如化学式1所示的第三类胺衍生物。【化学式1】（在上述化学式1中，各取代基的定义如本发明的详细说明所示。）